ASSESSMENT OF THE RELATIVE QUALITY-OF-LIFE IN PATIENTS RECEIVING SUBCUTANEOUS DEFEROXAMINE AND THE ORALLY-ACTIVE IRON-CHELATING AGENT L1

被引：0
|
作者：
BASRAN, RK [1 ]
FASSOS, FF [1 ]
SHAW, D [1 ]
OLIVIERI, NF [1 ]
机构：
[1] HOSP SICK CHILDREN,TORONTO M5G 1X8,ONTARIO,CANADA
来源：
BLOOD | 1994年 / 84卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A261 / A261
页数：1
相关论文
共 13 条
  • [1] THE 1ST PROSPECTIVE RANDOMIZED TRIAL OF SUBCUTANEOUS DEFEROXAMINE AND THE ORALLY-ACTIVE IRON-CHELATING AGENT L1
    OLIVIERI, NF
    SHER, GD
    MACKINNON, JA
    POPE, I
    ENTSUAH, B
    SNIDER, MA
    LEWIS, N
    SHAW, D
    BERKOVITCH, M
    KOREN, G
    BRITTENHAM, GM
    BLOOD, 1994, 84 (10) : A363 - A363
  • [2] THE FIRST PROSPECTIVE RANDOMIZED TRIAL OF SUBCUTANEOUS DEFEROXAMINE AND THE ORALLY-ACTIVE CHELATING AGENT
    POPE, E
    BERKOVITCH, M
    OLIVIERI, NF
    KOREN, G
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 57 (02) : 208 - 208
  • [3] EVIDENCE OF REDUCTION IN HEPATIC, CARDIAC AND PITUITARY IRON STORES IN PATIENTS WITH THALASSEMIA MAJOR DURING LONG-TERM THERAPY WITH THE ORALLY-ACTIVE IRON-CHELATING AGENT L1
    OLIVIERI, NF
    BELLUZZO, N
    MURACA, M
    MACKENZIE, CC
    MILONE, SD
    POLSINELLI, K
    KOREN, G
    LIU, PP
    BRITTENHAM, GM
    BLOOD, 1994, 84 (10) : A109 - A109
  • [4] Immune function in patients with beta thalassaemia receiving the orally active iron-chelating agent deferiprone
    Loebstein, R
    Dalal, I
    NisbetBrown, E
    Berkovitch, M
    Meydan, N
    Andrews, D
    Loubser, MD
    Koren, G
    Roifman, CM
    Olivieri, NF
    BRITISH JOURNAL OF HAEMATOLOGY, 1997, 98 (03) : 597 - 600
  • [5] SUCCESS, AND FAILURE, OF IRON CHELATION-THERAPY WITH THE ORALLY-ACTIVE IRON CHELATOR L1 IN 2 SISTERS
    MACKINNON, JA
    MILONE, SD
    BRITTENHAM, GM
    JACOB, RA
    KUTNINK, MA
    KOREN, G
    OLIVIERI, NF
    BLOOD, 1994, 84 (10) : A258 - A258
  • [6] Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to β-thalassemia
    Galanello, R
    Piga, A
    Alberti, D
    Rouan, MC
    Séchaud, R
    JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 43 (06): : 565 - 572
  • [7] Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1)
    Rombos, Y
    Tzanetea, R
    Konstantopoulos, K
    Simitzis, S
    Zervas, C
    Kyriaki, P
    Kavouklis, M
    Aessopos, A
    Sakellaropoulos, N
    Karagiorga, M
    Kalotychou, V
    Loukopoulos, D
    HAEMATOLOGICA, 2000, 85 (02) : 115 - 117
  • [8] Long-term followup of body iron in patients with thalassemia major during therapy with the orally active iron chelator deferiprone (L1).
    Olivieri, NF
    BLOOD, 1996, 88 (10) : 1229 - 1229
  • [9] Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1) (vol 85, pg 115, 2000)
    Rombos
    HAEMATOLOGICA, 2000, 85 (05) : 560 - 560
  • [10] Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis
    Arroyo Gonzalez, Rafael
    Kita, Mariko
    Crayton, Heidi
    Havrdova, Eva
    Margolin, David H.
    Lake, Stephen L.
    Giovannoni, Gavin
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (10) : 1367 - 1376
12